Local anesthetics take a central action in analgesia

Pain

Volumn 156, Issue 9, 2015, Pages 1579-1580

  Zeilhofer, Hanns Ulrich ^a,b   Schmelz, Martin ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; GLYCINE RECEPTOR; LOCAL ANESTHETIC AGENT; N ETHYLGLYCINE; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIA; CHRONIC PAIN; DRUG MECHANISM; HUMAN; MECHANICAL HYPERALGESIA; NOCICEPTION; NONHUMAN; NOTE; PAIN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; SPINAL CORD DORSAL HORN; SPINAL CORD NERVE CELL; SYNAPSE; SYNAPTIC INHIBITION; ANIMAL; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS;

ANESTHETICS, LOCAL; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; PAIN;

EID: 84952935066     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000233     Document Type: Note

References (20)

1. Attal N, Gaude V, Brasseur L, Dupuy M, Guirimand F, Parker F, Bouhassira D. Intravenous lidocaine in central pain: A double-blind, placebo-controlled, psychophysical study. Neurology 2000;54:564-74.
2. Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62:218-25.
3. Beato M. The time course of transmitter at glycinergic synapses onto motoneurons. J Neurosci 2008;28:7412-25.
4. Dohi T, Morita K, Kitayama T, Motoyama N, Morioka N. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol Ther 2009;123:54-79.
5. Foster E, Wildner H, Tudeau L, Haueter S, Ralvenius WT, Jegen M, Johannssen H, Hösli L, Haenraets K, GhanemA, Conzelmann KK, BöslM, Zeilhofer HU. Targeted ablation, silencing, and activation establish glycinergic dorsal horn neurons as key components of a spinal gate for pain and itch. Neuron 2015;85:1289-304.
6. Kastrup J, Angelo H, Petersen P, Dejgard A, Hilsted J. Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. Br Med J 1986;292:173.
7. Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M. Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. PAIN 2000;85:217-24.
8. Koppert W, Zeck S, Sittl R, Likar R, Knoll R, Schmelz M. Low-dose lidocaine suppresses experimentally induced hyperalgesia in humans. Anesthesiology 1998;89:1345-53.
9. Lindstrom P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. PAIN 1987;28:45-50.
10. Mitchell EA, Gentet LJ, Dempster J, Belelli D. GABAA and glycine receptor-mediated transmission in rat lamina II neurones: relevance to the analgesic actions of neuroactive steroids. J Physiol 2007;583: 1021-40.
11. Perńia-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF, Watanabe M, Filitz J, Koppert W, Schüttler J, Ji G, Neugebauer V, Marsicano G, Lutz B, Vanegas H, Zeilhofer HU. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 2009;325:760-4.
12. Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, Katner J, Gordon KD, Wade MR, Man T, Nomikos GG, Phebus LA, Cauvin AJ, Johnson KW, Jones CK, Hoffmann BJ, Sandusky GE, Walter MW, Porter WJ, Yang L, Merchant KM, Shannon HE, Svensson KA. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008;55:743-54.
13. Ralvenius WT, Benke D, Acunã MA, Rudolph U, Zeilhofer HU. Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype. Nat Commun 2015;6:6803.
14. Richards N, McMahon SB. Targeting novel peripheral mediators for the treatment of chronic pain. Br J Anaesth 2013;111:46-51.
15. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-8.
16. Sipila ST, Spoljaric A, Virtanen MA, Hiironniemi I, Kaila K. Glycine transporter-1 controls nonsynaptic inhibitory actions of glycine receptors in the neonatal rat hippocampus. J Neurosci 2014;34:10003-9.
17. Takazawa T,MacDermott AB. Glycinergic and GABAergic tonic inhibition fine tune inhibitory control in regionally distinct subpopulations of dorsal horn neurons. J Physiol 2010;588:2571-87.
18. Werdehausen R, Kremer D, Brandenburger T, Schlosser L, Jadasz J, Kury P, Bauer I, Aragon C, Eulenburg V, Hermanns H. Lidocaine metabolites inhibit glycine transporter 1: A novel mechanism for the analgesic action of systemic lidocaine? Anesthesiology 2012;116: 147-58.
19. Werdehausen R, Mittnacht S, McLaughlin LA, Minett MS, Armbruster A, Bauer I, Wood JN, Hermanns H, Eulenburg V. The lidocaine metabolite N-1 ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain. PAIN 2015: 156;1647-59.
20. Zeilhofer HU, Benke D, Yévenes GE. Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. Annu Rev Pharmacol Toxicol 2012;52:111-33.